Sanofi Acquires Vicebio for $1.6 Billion to Expand Vaccine Capabilities

Sanofi has completed the acquisition of Vicebio Limited from Medicxi Ventures and other investors for $1.6 billion. The acquisition brings an early-stage vaccine candidate for respiratory viruses RSV and hMPV and expands Sanofi's capabilities in vaccine design and development with Vicebio's "Molecular Clamp" technology. The consideration consists of an upfront payment of $1.15 billion and additional milestone payments of $450 million. The acquisition is expected to close in Q4 2025 and will not have a significant impact on Sanofi's financial guidance for 2025.